Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
May 28, 2026
Reporting period
Not applicable
Filed with the SEC
Jun 2, 2026
OfficerOption exercise
Context
Classification
option exercise
Code M — exercise or conversion of a derivative security
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001805688-26-000008
Filed / recorded
Jun 2, 2026, 12:06 AM UTC
Added to OQRO
Oct 6, 2026, 7:59 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Jazz Pharmaceuticals plc
Issuer CIK
1232524
Ticker
JAZZ
Reporting person
Samantha Pearce
Relationship
Officer
Officer title
EVP, Chief Commercial Officer
Security
Non-Qualified Stock Option (right to buy)
Table
Derivative (Table II)
Transaction date
May 28, 2026
Transaction code
M
Shares / units
6,907
Price per share
$0.00
Acquired / disposed
Disposed (D)
Shares owned after
0
Ownership form
Direct
Amendment
No
Footnotes from the filing
These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of March 2, 2020, 1/4th vested on the first anniversary of the vesting commencement date and the remainder vested in 36 equal monthly installments thereafter. The option was fully vested as of March 2, 2024.